HC Wainwright Increases Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Cytokinetics in a report issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of ($1.65) per share for the quarter, up from their prior forecast of ($1.80). HC Wainwright currently has a “Buy” rating and a $140.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($6.20) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2026 earnings at ($1.55) EPS and FY2026 earnings at ($6.38) EPS.

Cytokinetics (NASDAQ:CYTK) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to analyst estimates of $17.59 million. The company’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.12) EPS.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday. Wells Fargo & Company boosted their target price on shares of Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Truist Financial increased their target price on shares of Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research note on Monday. Needham & Company LLC raised their price target on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a report on Friday. Finally, Citigroup restated a “market outperform” rating on shares of Cytokinetics in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.15.

Cytokinetics Stock Performance

Shares of CYTK opened at $77.49 on Tuesday. Cytokinetics has a 52-week low of $32.89 and a 52-week high of $88.31. The business’s 50 day moving average price is $78.99 and its two-hundred day moving average price is $71.05. The firm has a market cap of $9.64 billion, a PE ratio of -10.73 and a beta of 0.39.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds have recently added to or reduced their stakes in CYTK. Millennium Management LLC increased its holdings in Cytokinetics by 361.9% during the 1st quarter. Millennium Management LLC now owns 287,901 shares of the biopharmaceutical company’s stock worth $11,571,000 after purchasing an additional 225,576 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of Cytokinetics by 12.4% in the second quarter. Cetera Investment Advisers now owns 6,635 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 731 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares in the last quarter. Gabelli Funds LLC boosted its position in shares of Cytokinetics by 29.4% during the second quarter. Gabelli Funds LLC now owns 8,410 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 1,910 shares during the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Cytokinetics by 10.8% during the second quarter. California Public Employees Retirement System now owns 142,602 shares of the biopharmaceutical company’s stock valued at $4,712,000 after buying an additional 13,911 shares during the last quarter.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 7,500 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total value of $636,900.00. Following the transaction, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at approximately $32,085,323.60. This trade represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the transaction, the executive vice president owned 58,555 shares of the company’s stock, valued at $4,337,754.40. This represents a 20.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 122,679 shares of company stock worth $9,701,754. Corporate insiders own 2.60% of the company’s stock.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright raised its 2026 earnings estimates, reducing its projected losses to $1.65 per share for the third quarter, $1.55 for the fourth quarter and $6.38 for full-year 2026. The firm maintained a “Buy” rating and a $140 price target, implying substantial upside from recent trading levels.
• Positive Sentiment: Several analysts have recently increased their valuation targets for CYTK, including Citizens JMP at $110 and Truist Financial at $112. The broader analyst consensus remains a “Moderate Buy,” with an average price target of approximately $101.15. Cytokinetics Price Target Raised to $110 Cytokinetics Price Target Raised to $112
• Positive Sentiment: The estimate revisions follow Cytokinetics’ recent quarterly results, in which it reported a smaller-than-expected loss and revenue above consensus forecasts. Those results may be reinforcing confidence in the company’s pipeline and future growth prospects.
• Neutral Sentiment: CEO Robert Blum sold 7,500 shares for approximately $575,700 at an average price of $76.76. The transaction was executed under a pre-arranged Rule 10b5-1 plan, leaving him with 377,820 shares; therefore, it appears less concerning than an unexpected discretionary sale. Insider Selling: Cytokinetics CEO Sells 7,500 Shares

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.